Ben Venue's Bedford Labs will assume Cetus Ben Venue oncology product line.
BEN VENUE TO BUY OUT CHIRON ONCOLOGY PRODUCTS JOINT VENTURE Cetus Ben Venue following Federal Trade Commission review of the transaction, which is expected to conclude in May, the companies announced April 22. Ben Venue's Bedford Labs generics business, which will assume the Cetus Ben Venue cancer drug injectable product line, will be able to ship products May 1, the company said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth